Search results for "Reducing"

showing 10 items of 139 documents

Effect of reducing agents on the acidification capacity and the proton motive force of Lactococcus lactis ssp. cremoris resting cells.

2002

International audience; Reducing agents are potential inhibitors of the microbial growth. We have shown recently that dithiothreitol (DTT), NaBH(4) and H(2) can modify the proton motive force of resting cells of Escherichia coli by increasing the membrane protons permeability [Eur. J. Biochem. 262 (1999) 595]. In the present work, the effect of reducing agents on the resting cells of Lactococcus lactis ssp. cremoris, a species widely employed in dairy processes was investigated. DTT did not affect the acidification nor the DeltapH, in contrast to the effect previously reported on E. coli. The DeltaPsi was slightly increased (30 mV) at low pH (pH 4) in the presence of 31 mM DTT or 2.6 mM NaB…

MESH : Cell LineMESH: Hydrogen-Ion ConcentrationMESH : DithioniteBorohydridesMESH : DithiothreitolBacterial growthmedicine.disease_causeMESH: Proton-Motive ForceDithiothreitolSodium dithionitechemistry.chemical_compoundMESH : Proton-Motive ForceElectrochemistry[INFO.INFO-BT]Computer Science [cs]/Biotechnology0303 health sciencesMESH : Interphasebiologyfood and beveragesProton-Motive ForceGeneral MedicineHydrogen-Ion ConcentrationMESH: BorohydridesLactococcus lactisMembraneBiochemistryReducing AgentsMESH : Sensitivity and SpecificityMESH : Reducing Agents[ INFO.INFO-BT ] Computer Science [cs]/BiotechnologyReducing agentMESH: Reducing AgentsBiophysics[SDV.BC]Life Sciences [q-bio]/Cellular BiologySensitivity and SpecificityCell LineMESH: Interphase03 medical and health sciencesSpecies SpecificityMESH : Hydrogen-Ion ConcentrationMESH: DithionitemedicineMESH : Species SpecificityMESH: Species SpecificityLactic AcidPhysical and Theoretical ChemistryEscherichia coli[SDV.BC] Life Sciences [q-bio]/Cellular BiologyInterphase030304 developmental biology[ SDV.BC ] Life Sciences [q-bio]/Cellular Biology030306 microbiologyChemiosmosisLactococcus lactisDithionitebiology.organism_classificationMESH: Sensitivity and SpecificityMESH: Cell LineDithiothreitol[INFO.INFO-BT] Computer Science [cs]/BiotechnologychemistryMESH: Lactococcus lactisMESH : BorohydridesMESH : Lactic AcidBiophysicsMESH: Lactic AcidMESH : Lactococcus lactisMESH: Dithiothreitol
researchProduct

Screening of lactic acid bacteria for reducing power using a tetrazolium salt reduction method on milk agar.

2013

WOS:000315703100020 ; www.elsevier.com/locate/jbiosc; International audience; Reducing activity is a physiological property of lactic acid bacteria (LAB) of technological importance. We developed a solid medium with tetrazolium dyes enabling weakly and strongly reducing LAB to be discriminated. It was used to quantify populations in a mixed culture (spreading method) and screen strains (spot method).

MESH: Oxidation-Reduction[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionTetrazolium Saltstetrazolium saltApplied Microbiology and Biotechnologychemistry.chemical_compoundAgarMESH: AnimalsFood science0303 health sciencesbiologyplate media04 agricultural and veterinary sciencesMESH: Tetrazolium SaltsSolid mediumLactic acidMilkMESH: AgarBiochemistryLactobacillaceaeMESH : AgarFormazanOxidation-ReductionBiotechnologyfood.ingredientMESH: LactobacillaceaeSpot methodBioengineering03 medical and health sciencesfoodoxidoreduction potentialMixed culturereducing powerAnimalsLactic AcidMESH : Tetrazolium SaltsMESH : Oxidation-Reduction030306 microbiologyscreeningMESH : Lactobacillaceae0402 animal and dairy scienceOxidation reductionbiology.organism_classification040201 dairy & animal scienceCulture MediaMESH: Milklactic acid bacteriaAgarchemistryMESH : MilkMESH : Lactic AcidMESH: Culture MediaMESH: Lactic AcidMESH : Culture MediaMESH : Animals[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBacteria
researchProduct

Weight reduction behaviors among European adolescents—Changes from 2001/2002 to 2017/2018.

2020

Ercan, Oya/0000-0001-7397-2837; Finne, Emily/0000-0002-6736-0022; Tesler, Riki/0000-0001-6070-6193; Ojala, Kristiina/0000-0001-9081-1891; Furstova, Jana/0000-0003-4057-2540; Dzielska, Anna/0000-0001-7396-8504 WOS:000538880700011 PubMed ID: 32446612 Purpose: The purpose of this study was to analyze changes in the prevalence of weight reduction behaviors (WRBs) among European adolescents from 26 countries between 2001/2002 and 2017/ 2018. The impact of the perception of body weight on WLB was also analyzed, with particular attention being paid to overestimation. Methods: The data of 639,194 European adolescents aged 11, 13, and 15 years who participated in the Health Behaviour in School-aged …

MaleGerontologyAdolescentDiet ReducingMEDLINEAdolescentsPediatricsBody Mass Index03 medical and health sciencesBMISex Factors0302 clinical medicineRegional developmentWeight loss030225 pediatricsWeight LossBody ImagePrevalencemedicineHumansObesity030212 general & internal medicineChildAdolescents; BMI; Overestimation of body weight; Trends; Weight perception; Weight reduction behaviorBody WeightEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthFoundation (evidence)PerinatologySelf ConceptDietPeer reviewSocial researchWeight perceptionEuropeand Child HealthOverestimation of body weightPsychiatry and Mental healthAdolescent BehaviorPediatrics Perinatology and Child HealthFemaleWeight reduction behaviorPublic Healthmedicine.symptomTrendsPsychology
researchProduct

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct

Eating habits, physical activity, consumption of substances and eating disorders in adolescents.

2011

The aim of this study was to evaluate the differences between adolescents with a high or low risk of developing an eating disorder (ED) in different health behaviors (eating habits, physical activity and the consumption of substances) per gender. The EAT-40 and the Inventory of Behavioral Health in Scholars were applied to 2142 middle school students from Alicante (Spain), of whom 52.8% were girls and 47.2% were boys, with an average age of 13.92 years old (Sd = 1.34). Results indicated that girls with a high risk of developing an ED consumed fewer meals, ate fewer unhealthy foods, followed more diets and paid more attention to nutritional components. Furthermore, they also performed more p…

MaleLinguistics and LanguageCalorieAnorexia NervosaAdolescentAlcohol DrinkingDiet ReducingSubstance-Related DisordersHealth BehaviorStatistics as TopicPhysical activityComorbidityMotor ActivityRisk AssessmentLanguage and LinguisticsDevelopmental psychologyWeight lossEnvironmental healthWeight LossmedicineHumansBulimiaEating habitsChildGeneral PsychologyConsumption (economics)SmokingFeeding Behaviormedicine.diseaseHealth SurveysEating disordersCross-Sectional StudiesSpainFemalemedicine.symptomPsychologyThe Spanish journal of psychology
researchProduct

Disulfide bridge formation between C1q and IgG in vitro.

1990

The globular heads of C1q are known to possess free-SH groups. Here we show that these groups, which are concealed in the native molecule, are exposed by interaction of C1q with dialysis membrane. During iodination, I+ and I2 oxidize these sulfhydryls to produce disulfide-linked C1q aggregates. Approximately 15% of C1q bound to immunoglobulin aggregates is resistant to high conductivity elution and reducing agent is required to release it. These data show that dialysis, adsorption to Ig and iodination of C1q result in structural and functional changes in the molecule, and suggest a mechanism by which these changes occur. Disulfide bridging between C1q and IgG in vitro suggests that this may…

MaleReducing agentImmunologyGuinea Pigschemical and pharmacologic phenomenaBiologyIn Vitro Techniquesurologic and male genital diseasesDialysis tubingfluids and secretionsimmune system diseasesImmunology and AllergyAnimalsSulfhydryl Compoundsskin and connective tissue diseasesComplement C1qComplement ActivationGel electrophoresisComplement C1qIn vitroBiochemistryImmunoglobulin Gbiology.proteinElectrophoresis Polyacrylamide GelFemaleAntibodyDialysis (biochemistry)CysteineEuropean journal of immunology
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effective low temperature reduction of graphene oxide with vanadium(iii)

2014

Reduction of graphene oxide (GO) with vanadium(III) trichloride under various reaction conditions has been investigated. The results show that V(III) can be used as an efficient reducing agent for GO in aqueous solutions at low concentrations and in moderate temperatures under ambient conditions. The IR spectroscopy and X-ray photoelectron spectroscopy (XPS) show that the structure of the vanadium-reduced material is similar to reduced graphene oxide prepared using TiCl3 or hydrazine as a reducing agent. The electrical conductivity of the material is also similar in all cases. However, on the basis of the XPS results, vanadium-based reduction does not leave significant reductant impurities …

Materials scienceAqueous solutionReducing agentGrapheneInorganic chemistryOxideInfrared spectroscopyVanadiumchemistry.chemical_elementGeneral ChemistryRedoxlaw.inventionchemistry.chemical_compoundchemistryX-ray photoelectron spectroscopylawMaterials Chemistryta116Journal of Materials Chemistry. C
researchProduct

Formation and Growth of Pd Nanoparticles Inside a Highly Cross-Linked Polystyrene Support: Role of the Reducing Agent

2014

Simultaneous time-resolved SAXS and XANES techniques were employed to follow in situ the formation of Pd nanoparticles in a porous polystyrene support, using palladium acetate as a precursor and gaseous H2 or CO as reducing agents. These results, in conjunction with data obtained by diffuse reflectance UV–vis and DRIFT spectroscopy and TEM measurements, allowed unraveling of the different roles played by gaseous H2 and CO in the formation of the Pd nanoparticles. In particular, it was found that the reducing agent affects (i) the reduction rate (which is faster in the presence of CO) and (ii) the properties of the hosted nanoparticles, in terms of size (bigger with CO), morphology (spherica…

Materials scienceExtended X-ray absorption fine structureReducing agentSmall-angle X-ray scatteringchemistry.chemical_elementNanoparticlePd nanoparticles; SAXS; EXAFSSAXSXANESSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsCrystallographychemistry.chemical_compoundEXAFSGeneral EnergyPd nanoparticleschemistryChemical engineeringPalladium nanoparticles time-resolved X-ray Absorption Spectroscopy Small Angle X-ray Spectroscopy Transmission Electron MicroscopyDiffuse reflectionPolystyrenePhysical and Theoretical ChemistryPalladium
researchProduct

Oxide-based nanomaterials for fuel cell catalysis:the interplay between supported single Pt atoms and particles

2017

The concept of single atom catalysis offers maximum noble metal efficiency for the development of low-cost catalytic materials. Among possible applications are catalytic materials for proton exchange membrane fuel cells. In the present review, recent efforts towards the fabrication of single atom catalysts on nanostructured ceria and their reactivity are discussed in the prospect of their employment as anode catalysts. The remarkable performance and the durability of the ceria-based anode catalysts with ultra-low Pt loading result from the interplay between two states associated with supported atomically dispersed Pt and sub-nanometer Pt particles. The occurrence of these two states is a co…

Materials sciencePHOTOELECTRON-SPECTROSCOPYReducing agentCatalitzadorsOxideProton exchange membrane fuel cellNanotechnology02 engineering and technologyengineering.material010402 general chemistry01 natural sciencesRedoxPALLADIUM NANOPARTICLESCatalysisNanomaterialsCatalysischemistry.chemical_compoundAdsorptionPiles de combustibleD-METAL ATOMSFuel cellsCatalystsCEO2(111) SURFACECO OXIDATIONIN-SITUNanostructured materialsSILICON SUBSTRATE021001 nanoscience & nanotechnology0104 chemical scienceschemistryChemical engineeringGRAPHITE FOILengineeringTHIN-FILM CATALYSTSNoble metalMaterials nanoestructuratsCERIA-BASED OXIDE0210 nano-technology
researchProduct